Opinion|Videos|August 20, 2024

Comparing Cretostimogene and BCG Administration Methods

Author(s)Trinity Bivalacqua, MD, PhD, Mark D. Tyson, MD, MPH

Experts compare Cretostimogene and BCG Administration Methods

Episodes in this series

EP. 1 Prevalence and Staging of Newly Diagnosed Bladder Cancer

EP. 1 Prevalence and Staging of Newly Diagnosed Bladder Cancer

EP. 2 Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

EP. 2 Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 3 Recurrence and BCG Resistance in High-Risk NMIBC

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 4 Therapies Beyond BCG: FDA-Approved and Emerging Options

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 5 Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 6 CORE-001 Trial Participation and Eligibility Criteria

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 7 Comparing Cretostimogene and BCG Administration Methods

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 8 Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 9 Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 10 Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 11 Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 12 Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination Therapy

Video content above is prompted by the following questions:

Can you describe the therapy dose, mode of administration, and duration?
How does the administration method of cretostimogene compare to that of BCG?
What were the primary and secondary endpoints of this trial?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Emanuele Crupi, MD, highlights phase 2 trial of GemFLP in urinary tract adenocarcinomas

ByEmanuele Crupi, MD

August 27th 2026

Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer

ByHannah Clarke

August 26th 2026

FDA receives NDA submission for UGN-103 in recurrent LG-IR-NMIBC

ByHannah Clarke

August 17th 2026

Nima Almassi, MD, highlights long-term data on bladder preservation in MIBC

ByNima Almassi, MD

August 13th 2026

Blue light cystoscopy is tied to higher resource use, not health care cost, in NMIBC

ByHannah Clarke

August 11th 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Initial prostate cancer presentation, family history linked to survival in mCRPC

State of Men’s Health Act: What urologists need to know

Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment

FDA greenlights phase 1 trial of ADI-212 in mCRPC

Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer